Non-small Cell Lung Cancer Study US75 (Z-PACT) (ZPACT)
Non Small Cell Lung Carcinoma

About this trial
This is an interventional prevention trial for Non Small Cell Lung Carcinoma focused on measuring lung cancer, ZPACT, US75, Bone Metastases
Eligibility Criteria
Inclusion Criteria: Male or Female patients at least of 18 years old Patients with diagnosed non-small cell lung cancer that cannot be treated by surgery Women must not be pregnant or attempting to become pregnant Able and willing to sign informed consent Exclusion Criteria: Patients with cancer that has spread to the bone Patients with cancer that has spread to the brain who are receiving treatment Patients with kidney disease Patients treated with other investigational drugs
Sites / Locations
- Clinical Research Consultants
- Arizona Oncology Assoc.
- NEA Clinic
- Highlands Oncology Group
- NorthBay Cancer Center
- UCLA
- Clinical Trials and Research Associates, Inc.
- Med. Oncology Care Associates
- Cancer Center of Santa Barbara
- Cancer Center of Colorado Springs
- Northern Hematology-Oncology
- Lynn Regional Cancer Center
- New Hope Cancer Centers
- Oceola Cancer Center
- Innovative Medical Research of South Florida, Inc.
- VA Medical Center
- NCH Healthcare System Oncology Research
- Metcare Oncology
- Hematology-Oncology Associates
- AMIT SHAH Medical Group
- Peachtree Hematology & Oncology
- Emory University
- Straub Clinic & Hospital
- Kaiser Foundation Hospital
- Advocate Illinois Masonic Medical Center Creticos Cancer Center
- OSF Center for Cancer Care
- Springfield Clinic, LLP
- Central Indiana Cancer Centers
- Oncology Institute of Greater Lafayette
- Community Hospital, Cancer Research Dept.
- Northern Indiana Oncology Associates
- Cedar Valley Medical Specialists
- Kansas City Cancer Ctr. South
- Hematology/Oncology Clinic
- Mary Bird Perkins Cancer Center
- LSU Health Sciences Center
- Maine Center for Cancer Medicine
- Oncology Care Associates
- Berkshire Hematology Oncology PC
- Karmanos Cancer Institute
- Kalamazoo Hematology & Oncology
- Mitchell Folbe, MD, PC
- Park Nicollett Institute
- St. Louis Cancer Care
- Southeast Nebraska Cancer Center
- Odyssey Research
- Southern Nevada Cancer Research Foundation
- Nevada Cancer Center
- East Orange VA Medical System
- Howell Office Plaza
- Atlantic Hem Onc Associates, LLC
- Hematology/Oncology Assoc. of South Jersey
- Cancer Institute of New Jersey at Cooper University Hospital
- New Mexico Oncology Hematology Consultants, Ltd.
- San Juan Regional Cancer Ctr.
- New Mexico Cancer Care Associates
- Engracio Cortes, MD
- Arena Oncology Assoc.
- James P. Wilmot Cancer Center
- SUNY Upstate Medical University
- Syracuse VA Medical Center
- Presbyterian Hospital
- Southern Oncology Research
- Barberton Citizens Hospital-Cancer Center
- Dayton Clinical Oncology Program
- Forum Health Cancer CareCenter
- Cancer Specialists of Oklahoma
- Hematology Oncology Associates
- Charleston Hematology Oncology
- Charleston Cancer Center
- Liberty Hematology-Oncology
- Santee Hematology/Oncology
- The Jones Clinic
- Knoxville Cancer Center
- Cancer Specialists of South Texas
- Blood and Cancer Center of East Texas
- Tyler Hematology Oncology, PA
- Odyssey Research
- Masoom Kandahari, MD
- West Virginia University
Arms of the Study
Arm 1
Arm 2
Experimental
No Intervention
Zometa®
no further treatment
4mg monthly for 12 months from date of first chemotherapy dose
Control arm; no further treatment. Follow-up monthly for 12 months from date of first chemotherapy dose